Objective: The aim of this study was to compare quality of life (QOL) in small unilateral vestibular schwannoma (VS) patients managed by microsurgery, radiotherapy or observation.
| INTRODUCTION
Vestibular schwannoma (VS) is a benign tumour arising from the Schwann cell sheath of the vestibular part of the eighth cranial nerve.
The most common diagnostic symptoms are cochleovestibular symptoms such as unilateral hearing loss, tinnitus and vertigo.
Other clinical symptoms such as facial hypoesthesia, facial nerve paralysis and intracranial hypertension appear only with larger tumours.
Since the 70th, the diagnosis of small VS was already a routine procedure with invasive neuroradiological procedures. With widespread access and improved magnetic resonance imaging (MRI) techniques, VS can nowadays be detected incidentally and earlier with an increasing number of patients presenting with small tumours and few symptoms. Moreover, the natural history of VS growth is now well known 2 and the majority of tumours are slowgrowing. 3, 4 The best management remains controversial for small-and medium-sized VS tumours. Treatments include observation, radiotherapy (RT) and microsurgery (MS) via a hearing preservation (retrosigmoid or middle fossa approach) or translabyrinthine approach. The choice of treatment depends on several criteria such as patient age, comorbidity, tumour size and location, hearing status and patient preference.
In recent decades, quality of life (QOL) has become an important issue for patients and clinicians to decide the best treatment option.
The aim of this study was to analyse data from four questionnaires, the Short-Form Health Survey 36 (SF-36), the Hearing Handicap Inventory (HHI), the Tinnitus Handicap Inventory (THI) and the Dizziness Handicap Inventory Short-Form (DHI short-form), that assess QOL to compare the outcomes of MS, RT and observation for VS stages 1 and 2 according to the Koos classification. 5 We thought to establish factors predictive of worse QOL in each group.
| ETHICAL CONSIDERATIONS
The university hospital ethics committee approved the study.
| MATERIAL AND METHODS

| Design
This retrospective monocentric study included all patients from January 2004 to December 2015 presenting unilateral VS stage 1 or 2 according to the Koos classification in a tertiary care centre.
| Criteria of selection
A total of 168 patients with VS stage 1 (VS in the internal auditory meatus) or 2 (VS in the internal auditory meatus and cerebellopontine angle without any touch the brainstem) of Koos classification were managed in our centre including 64 patients who underwent observation, 53 who received RT and 51 who underwent MS. Exclusion criteria were neurofibromatosis type 2, tumour stages 3 or 4 and age younger than 18 years. Patients were divided into three treatment groups: observation group, RT group with Gamma Knife ® or CyberKnife ® and MS group with translabyrinthine or middle fossa approach.
| Data
Size of tumour was measured by MRI in axial constructive interference in steady state (CISS) T2. Pre-and post-therapeutic data were collected: hearing level graded by the Gardner-Robertson scale 6 ; hearing threshold deterioration between initial diagnosis and just before treatment for radiotherapy and microsurgery and between diagnosis and last news for the observation group; facial function using the HouseBrackmann scale 7 ; and clinical symptoms such as tinnitus and vertigo, postsurgical or radiation complications and recurrent tumours. Hearing preservation was correlated with invasion of internal auditory meatus fundus, invasion of the cochlear fossa, and intensity of cochlear fluid T2 as compared to contralateral one.
| Questionnaires
QOL was assessed using four questionnaires. All patients completed four questionnaires (SF-36, HHI, THI and DHI short-form).
The SF-36 is a validated questionnaire used to assess the general QOL of patients following surgical or medical therapies. It consists of 36 items and assesses 8 different health conditions including physical functioning, role limitations due to physical or emotional problems, body pain, general health, vitality, social functioning and mental health. 8 It also provides a physical component summary score and a mental component summary score. Scores range from 0 to 100, higher scores meaning better QOL. The HHI questionnaire assesses five social questions and five emotional questions and gives a total score, an emotional score and a social score. 9 The answer "yes" gives 4 points, "sometimes" 2 points and "no" zero points. A overall score over eight points exhibits a lack in QOL related to hearing loss. The THI is a 25-item questionnaire that classifies tinnitus intensity in five categories: from mild to catastrophic. 10 The DHI short-form evaluates the functional, emotional and physical effects of dizziness and contains 13 questions: 5 on physical function, 2 on emotional function and 6 on functional issues. 
| Statistical analyses
Quantitative variables were described as mean ± standard deviation.
Comparisons of baseline demographics, clinical outcomes and HRQOL outcomes in the three groups were evaluated using the Qualitative parameters: effective (%), χ 2 test(K) and Fisher (F).
Quantitative parameters: mean ± standard deviation, Kruskal-Wallis tests (KW). PTA auditory thresholds: calculated on mean of thresholds for frequencies 500, 1000, 2000 and 3000 Hz (dB HL). HB: House and Brackmann facial nerve grading scale. Hearing deterioration: Hearing threshold deterioration in dB between initial diagnosis and just before treatment for radiotherapy and microsurgery, and between diagnosis and last news for the observation group, calculated on mean of thresholds for frequencies 500, 1000, 2000 and 3000 Hz (dB HL). Hearing deterioration per month: Hearing threshold deterioration per month in dB between initial diagnosis and just before treatment for radiotherapy and microsurgery, and between diagnosis and last news for the observation group, calculated on mean of thresholds for frequencies 500, 1000, 2000 and 3000 Hz (dB HL). In the observation group, 6 patients (11.3%) had growing tumour and 47 (88.7) had stable tumours. The mean growth was 1.27 ± 0.69 per year. There was no correlation between hearing loss and VS growth (P = 0.1790).
Radiological features were studied as a function of hearing loss after treatment. No correlation was observed between hearing loss after treatment and invasion of internal auditory meatus fundus (P = 0.4182 for RT group; P = 0.1282 for MS group), invasion of the cochlear fossa (P = 0.1996 for RT group; P = 0.0633 for MS group), and intensity of cochlear fluid T2 signal as compared to contralateral one (P = 0.7133 for RT group; P = 0.4058 for MS group). Table 3 One patient presented a residual tumour treated secondarily by radiation.
In the RT group, 4 patients (8.7%) underwent a surgical resection.
One patient was operated 1 year after RT for a tumour that grew from 12 to 22 mm. Two patients were operated 2 years after RT for a tumour growth of from 10 to 15 mm and from 9 to 16 mm. One patient was operated 3 years after RT for a tumour growth from 17 to 28 mm. Tumour growth rate was the same before and after treatment, and all of these patients were treated by GammaKnife. There was no difference in SF-36 scores between these four patients and the other patients of the RT group. There was no difference between tumour control (P = 1.00) and hearing preservation (P = 0.17)
between treatment by GammaKnife and treatment by CyberKnife. Table 4 . There were no differences between the three groups for physical (P = 0.67) or mental health measures (P = 0.59). No difference for physical or mental health measures were found between middle fossa or translabyrinthine approach. Wilcoxon physical score P = 0.36, mental score P = 0.65).
There was no significant difference between the groups for total HHI, emotional HHI, social HHI or auditory disorders (Table 6) . Furthermore, there was no significant difference between the groups for any THI scores (Table 7 ). There were no significant differences across management options between scores on the global DHI test and on the emotional, functional and physical DHI tests (Table 8 ). In the MS group, there were no significant differences in the results obtained from the four questionnaires between the two approaches (Mann-Whitney Wilcoxon 0.40 < P < 0.96). A multivariant analysis suggested that time to management had no impact on the results obtained on any of the questionnaires and in any of the patients in the study (ANCOVA 0.26 < P < 0.99).
| DISCUSSION
There were no significant differences in QOL using the SF-36 questionnaires between the three groups. While numerous studies have evaluated VS outcomes, the best management of patients with small VS is still controversial and issues relating to QOL are of paramount importance. To our knowledge, this is the first retrospective study to use a global QOL questionnaire and specific questionnaires to quantify impaired QOL due to hearing loss, dizziness and tinnitus in observation, RT and MS groups.
In a prospective study with these three groups, Di Maio et al 12 did not find any difference in QOL. Robinett et al 13 found that between 1 and 5 years postmanagement, the RT group had higher QOL scores than the MS group, while there was no difference after 5 years. Pollock et al 14 showed that within 3 months after surgery, patients had a statistically significant decline in several of the SF-36 domains such as physical functioning, role physical, energy and overall physical. After 3 months of follow-up, there was no difference between the RT and MS groups. The mean follow-up for our three groups was 66 months (61, 57 and 81 months for the observation, RT and MS groups, respectively) ( Table 2) , so this cannot explain why we did not find any difference. Our patients in the observation group had smaller tumours, as also reported by Di Maio et al. 12 They were older than the remnant of the cohort, and the MS group was younger than the other two groups, as in the studies by Carlson et al 15 and Pollock et al. 14 Gauden et al 16 showed that the SF-36 was the most common questionnaire used to study QOL in SV. Different studies have compared the three groups and found different results. Carlson et al 15 and Myrseth et al 17 found no difference between the three groups.
Kim et al 18 found that QOL was greater after MS than after RT.
Three studies showed that MS patients had worse QOL than those in the other groups. 14, 19, 20 Soulier et al 21 reported better QOL in patients with small tumours (<10 mm) undergoing observation because there was no active treatment, so patients did not feel sick. correlation with tumours extending to the cerebellopontine cistern.
As Lee et al, 27 we found no correlation between the audiometric results and the degree of the signal increase in the cochlea or invasion of the cochlear fossa or invasion of the internal auditory meatus fundus.
There was no difference in SF-36 results in patients with or without facial palsy. Facial palsy obviously affects QOL so this finding was probably due to a lack of pertinence of the questionnaires regarding this symptom. Kelleher et al 28 found the same conclusion with the SF-36.
In our study, tinnitus was a prognostic factor of impaired QOL only in the MS group, whereas Lloyd et al 24 and Kim JH et al 18 found it to be a significant symptom in the observation group. Vertigo was a predictive symptom of reduced QOL in the three groups, as already reported elsewhere. Four studies 24, 25, 28, 29 showed that dizziness was the most significant audio-vestibular predictor of QOL when management was conservative (observation or RT). Patients who were observed or who had RT had residual ipsilateral symptoms owing to unilateral vestibular hypofunction, and most subjects in the MS group reported central compensation with a significant improvement in symptoms after a period of several weeks or months.
Vestibular rehabilitation could improve balance disorder by allowing central compensation.
As the study was retrospective, the delay between management and evaluation was different between patients with a longer delay in the MS group and those in the RT group. However, multivariate analysis did not find that the difference in delay influenced the responses on the questionnaires. Differences in delay between the groups may be explained by the therapeutic attitude in our centre, which was more surgical in the early 2000s and has since become more conservative. Small tumours are operated via a translabyrinthine approach when the preoperative hearing level is not sufficient for understanding speech and via the middle fossa approach to preserve hearing.
In our study, 7 patients were treated by CyberKnife in three sessions of 6.5 Gy vs 39 by GammaKnife in a single session of 12 Gy and there was no difference between tumour control and hearing between these two treatments. A study of Combs et al 30 found that local control of VS was 97% at 36 months, 95% at 60 months and 94% at 120 months with no difference between fractionated dose or single dose of RT (P = 0.39). After RT, hearing preservation was observed in 85% of the patients. Loss of hearing was the same in both groups.
In our study, patients in the control group were older than the other groups. Tumour growth was less important in a subject who has a limited life expectancy. There is no treatment indication for VS stage 1 and no acceptable treatment for VS stage 2 in the elderly. 31 Tumour growth and Koos stage in the observation group were smaller than the other groups. Even though there is no risk of brainstem compression in a short-term time frame, this is an argument which prescribes for observation in the VS stage 1 group. The risk of facial nerve palsy was 13.9% in the MS group, 20% and 10% for middle fossa and translabyrinthine approach, respectively. This is, again, another argument for a nonintervention in small tumours, even if there is no difference between the QOL questionnaires among the MS and the other groups.
Hearing deterioration was limited in the control group, more advanced in the RT group and higher in the MS group. These data suggest that patients with functional hearing have to be observed. Vertigo is the principal cause of QOL deterioration in the management of VS.
